Metabolic syndrome components and their response to lifestyle and metformin interventions are associated with differences in diabetes risk in persons with impaired glucose tolerance

Diabetes, Obesity and Metabolism

Volumn 16, Issue 4, 2014, Pages 326-333

  Florez, H ^a   Temprosa, M G ^b   Orchard, T J ^c   Mather, K J ^d   Marcovina, S M ^e   Barrett Connor, E ^f   Horton, E ^g   Saudek, C ^h   Pi Sunyer, X F ⁱ   Ratner, R E ^j,k   Goldberg, R B ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b GEORGE WASHINGTON UNIVERSITY   (United States)

^c UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^d INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g JOSLIN DIABETES CENTER   (United States)

^h JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ Columbia University College of Physicians and Surgeons ^*  (United States)

^j MEDSTAR RESEARCH INSTITUTE   (United States)

^k AMERICAN DIABETES ASSOCIATION   (United States)

more..

Author keywords

Cardiometabolic risk; Diabetes prevention; Lifestyle; Metformin

Indexed keywords

GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PLACEBO; TRIACYLGLYCEROL; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INTENTION TO TREAT ANALYSIS; LIFESTYLE MODIFICATION; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MIDDLE AGED; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; AGE; BLOOD; CARDIOVASCULAR DISEASES; CLINICAL TRIAL; COMPLICATION; CONTROLLED STUDY; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIET RESTRICTION; EXERCISE; GLUCOSE INTOLERANCE; INCIDENCE; LOW CALORY DIET; METABOLISM; MULTICENTER STUDY; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; REMISSION; RISK FACTOR; RISK REDUCTION;

AGE FACTORS; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIET, REDUCING; EXERCISE; FASTING; FEMALE; GLUCOSE INTOLERANCE; HUMANS; HYPOGLYCEMIC AGENTS; INCIDENCE; MALE; METABOLIC SYNDROME X; METFORMIN; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; REMISSION INDUCTION; RISK FACTORS; RISK REDUCTION BEHAVIOR; TRIGLYCERIDES; WAIST CIRCUMFERENCE;

EID: 84895123215     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12220     Document Type: Article

References (31)

1. Lorenzo C, Okoloise M, Williams K et al. San Antonio Heart Study. The metabolic syndrome as predictor of type 2 diabetes: the San Antonio heart study. Diabetes Care 2003; 26: 3153-3159.
2. Wilson PW, D'Agostino RB, Parise H et al. Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation 2005; 112: 3066-3072.
3. Henry RM, Kostense PJ, Spijkerman AM et al. Arterial stiffness increases with deteriorating glucose tolerance status: the Hoorn Study. Circulation 2003; 107: 2089-2095.
4. Yasuno S, Ueshima K, Oba K et al. Is pulse pressure a predictor of new-onset diabetes in high-risk hypertensive patients? A subanalysis of the Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial. Diabetes Care 2010; 33: 1122-1127.
5. Després JP, Lemieux I, Bergeron J et al. Abdominal obesity and the metabolic syndrome: contribution to global cardiometabolic risk. Arterioscler Thromb Vasc Biol 2008; 28: 1039-1049.
6. Diabetes Prevention Program Research Group, Knowler WC, Barrett-Connor E, Fowler SE et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393-403.
7. Diabetes Prevention Program Research Group. The Diabetes Prevention Program: design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care 1999; 22: 623-634.
8. Phillips DI, Clark PM, Hales CN, Osmond C. Understanding oral glucose tolerance: comparison of glucose or insulin measurements during the oral glucose tolerance test with specific measurements of insulin resistance and insulin secretion. Diabet Med 1994; 11: 286-292.
9. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report on the Expert Committee on Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997; 20: 1183-1197.
10. World Health Organization. Diabetes mellitus: report of a WHO Study Group. Geneva: World Health Organization, 1985. Technical Report Series No. 727.
11. Grundy SM, Brewer HB Jr, Cleeman JI et al. American Heart Association; National Heart, Lung, and Blood Institute. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004; 109: 433-438.
12. Alberti KG, Zimmet P, Shaw J. The metabolic syndrome: a new worldwide definition. Lancet 2005; 366: 1059-1062.
13. Cox DR. Regression models and life-tables. J R Stat Soc B 1972; 34: 187-220.
14. Lachin JM. Biostatistical Methods: The Assessment of Relative Risks. New York: John Wiley and Sons, 2000.
15. Orchard TJ, Temprosa M, Goldberg R et al. Diabetes Prevention Program Research Group. The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial. Ann Intern Med 2005; 142: 611-619.
16. Wilson PW, Meigs JB, Sullivan L et al. Prediction of incident diabetes mellitus in middle-aged adults: the Framingham Offspring Study. Arch Intern Med 2007; 167: 1068-1074.
17. Kelley DE, Goodpaster BH, Storlien L. Muscle triglyceride and insulin resistance. Annu Rev Nutr 2002; 22: 325-346.
18. Janiszewski PM, Janssen I, Ross R. Does waist circumference predict diabetes and cardiovascular disease beyond commonly evaluated cardio-metabolic risk factors? Diabetes Care 2007; 30: 3105-3109.
19. Freemantle N, Holmes J, Hockey A, Kumar S. How strong is the association between abdominal obesity and the incidence of type 2 diabetes? Int J Clin Pract 2008; 62: 1391-1396.
20. The Diabetes Prevention Program Research Group. Relationship of body size and shape to the development of diabetes in the Diabetes Prevention Program. Obesity 2006; 14: 2107-2117.
21. The Diabetes Prevention Program Research Group. Lipid, lipoproteins, C-reactive protein, and hemostatic factors at baseline in the diabetes prevention program. Diabetes Care 2005; 28: 2472-2479.
22. Lachin JM, Christophi CA, Edelstein SL et al. for the Diabetes Prevention Program Research Group. Factors associated with diabetes onset during metformin versus placebo therapy in the Diabetes Prevention Program. Diabetes 2007; 56: 1153-1159.
23. Fagot-Campagna A, Knowler WC et al. HDL cholesterol subfractions and risk of developing type 2 diabetes among Pima Indians. Diabetes Care 1999; 22: 271-274.
24. Gress TW, Nieto FJ, Shahar E et al. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study. N Engl J Med 2000; 342: 905-912.
25. Serné EH, de Jongh RT, Eringa EC et al. Microvascular dysfunction: a potential pathophysiological role in the metabolic syndrome. Hypertension 2007; 50: 204-211.
26. Levy BI, Schiffrin EL, Mourad JJ et al. Impaired tissue perfusion: a pathology common to hypertension, obesity, and diabetes mellitus. Circulation 2008; 118: 968-976.
27. Fontbonne A, Diouf I, Baccara-Dinet M et al. Effects of 1-year treatment with metformin on metabolic and cardiovascular risk factors in non-diabetic upper-body obese participants with mild glucose anomalies: a post-hoc analysis of the BIGPRO1 trial. Diabetes Metab 2009; 35: 385-391.
28. Goldberg RB, Temprosa M, Haffner S et al. Effect of progression from impaired glucose tolerance to diabetes on cardiovascular risk factors and its amelioration by lifestyle and metformin intervention: the Diabetes Prevention Program randomized trial by the Diabetes Prevention Program Research Group. Diabetes Care 2009; 32: 726-732.
29. Mannucci E, Monami M, Bardini G et al. Metabolic syndrome and pulse pressure. Diabetes Obes Metab 2007; 9: 600-602.
30. Alberti KG, Eckel RH, Grundy SM et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120: 1640-1645.
31. Dunkley AJ, Charles K, Gray LJ et al. Effectiveness of interventions for reducing diabetes and cardiovascular disease risk in people with metabolic syndrome: systematic review and mixed treatment comparison meta-analysis. Diabetes Obes Metab 2012; 14: 616-625.